CuraGen Corporation CEO Jonathan Rothberg Talks to the Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Sept. 19, 2002 The Wall Street Transcript has published an in-depth interview with Jonathan Rothberg, Ph.D., Chairman, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and President of CuraGen Corporation (Nasdaq:CRGN), in which he discusses the Company's business strategy. The entire 3,400 word interview is available free online at http://www.twst.com/ceos.htm Dr. Rothberg gives an overview of the Company, "CuraGen was born out of the convergence between the information technology and the genomics revolutions. It has been our goal from the start to meld those two disciplines into a high-throughput system that would enable CuraGen scientists to discover and develop a sustainable pipeline of pharmaceutical products." Jonathan explains, "Our relationships with Abgenix and Bayer are ideal because we leverage each other's respective strengths, share the risks involved in drug development, but most importantly Adv. 1. most importantly - above and beyond all other consideration; "above all, you must be independent" above all, most especially , share substantially in the results of our collaborative efforts." Looking forward, Jonathan states, "The first meaningful revenues that come from a CuraGen-derived pharmaceutical may not come from a marketed drug, but instead, will most likely come from a product that we partner. We believe this to be the most likely scenario because of the shear number of projects that we have under way at CuraGen." CuraGen Corporation (Nasdaq:CRGN) is a genomics-based pharmaceutical company. CuraGen's integrated, functional genomic technologies and Internet-based bioinformatic systems are designed to generate comprehensive information about genes, human genetic variations, gene expression, protein interactions, protein pathways, and potential drugs that affect these pathways. The Company is applying its industrialized in·dus·tri·al·ize v. in·dus·tri·al·ized, in·dus·tri·al·iz·ing, in·dus·tri·al·iz·es v.tr. 1. To develop industry in (a country or society, for example). 2. genomic technologies, informatics Same as information technology and information systems. The term is more widely used in Europe. , and validation technologies to develop protein, antibody, and small molecule therapeutics to treat obesity and diabetes, cancer, inflammatory diseases, and central nervous system (CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ) disorders. CuraGen is headquartered in New Haven New Haven, city (1990 pop. 130,474), New Haven co., S Conn., a port of entry where the Quinnipiac and other small rivers enter Long Island Sound; inc. 1784. Firearms and ammunition, clocks and watches, tools, rubber and paper products, and textiles are among the many , CT. Additional information is available at http://www.curagen.com. This interview is part of a 472-page Bear, Stearns & Co. 15th Annual Healthcare Conference Issue available at http://www.twst.com/info/info616.htm or by calling 212/952-7433 The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. This press release may contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. including statements about CuraGen scientists' ability to discover and develop a sustainable pipeline of pharmaceutical products, CuraGen's ability to generate results from its collaborative efforts with Abgenix and Bayer, and CuraGen's ability to have meaningful revenues from a partnered product. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. CuraGen cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: CuraGen's expectation that it will incur operating losses operating loss The excess of operating expenses over revenue. As with operating income, operating losses exclude revenues and expenses from operations that are not considered a regular part of the business. Also called deficit. Compare operating income. in the near future, the early stage of development of CuraGen's products and technologies, uncertainties related to preclinical and clinical testing and trials, uncertainties and adverse results relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc CuraGen's ability to obtain regulatory approval for its products in development, uncertainties surrounding the availability of additional funding, CuraGen's reliance on research collaborations and strategic alliances, the actions of competitors, the development of competing technologies, CuraGen's ability to protect its patents and proprietary rights, patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. actions and uncertainties relating to commercialization rights. Please refer to our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 2001 for a description of these risks. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion